A Phase Ib, Open-label Study of Safety and Pharmacokinetics of Volitinib in Combination With Docetaxel in Patients With Advanced Gastric Cancer

Trial Profile

A Phase Ib, Open-label Study of Safety and Pharmacokinetics of Volitinib in Combination With Docetaxel in Patients With Advanced Gastric Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Docetaxel (Primary) ; Savolitinib (Primary)
  • Indications Gastric cancer
  • Focus Adverse reactions
  • Sponsors Hutchison MediPharma
  • Most Recent Events

    • 29 Sep 2017 According to a Chi-Med media release, results were presented at the Chinese Society of Clinical Oncology (CSCO) 2017.
    • 29 Sep 2017 Results presented in a Chi-Med media release.
    • 01 Aug 2016 According to Chi-Med and AstraZeneca media release, first patient dosed in advanced gastric adenocarcinoma with second-line MET gene amplified patients during Q4 2014 and for Second-line MET overexpression patients during 4 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top